4
Changes in Ownership
Viking Therapeutics, Inc. Filed Acc 0001209191-24-003010
President & CEO sold 269,079 shares at an average $26.87 ($7,230,784)
- President & CEO acquired 189,079 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Lian Brian · President & CEO
Table I: Non-derivative
7 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-02-08 | Exercise or conversion : show line 1 in the form 10b5-1 | +49,079 | $1.23 | $60,367 | 2,313,961 | D |
| 2024-02-08 | Sale : show line 2 in the form 10b5-1 | −49,079 | $25.75 | $1,263,784 | 2,264,882 | D |
| 2024-02-08 | Exercise or conversion : show line 3 in the form 10b5-1 | +140,000 | $4.65 | $651,000 | 2,404,882 | D |
| 2024-02-08 | Sale : show line 4 in the form 10b5-1 | −60,000 | $25.95 | $1,557,000 | 2,344,882 | D |
| 2024-02-08 | Sale : show line 5 in the form 10b5-1 | −80,000 | $26.95 | $2,156,000 | 2,264,882 | D |
| 2024-02-08 | Sale : show line 6 in the form 10b5-1 | −40,000 | $27.45 | $1,098,000 | 2,224,882 | D |
| 2024-02-08 | Sale : show line 7 in the form 10b5-1 | −40,000 | $28.90 | $1,156,000 | 2,184,882 | D |
| Open-market sales · 269,079 sh · avg $26.87 · $7,230,784 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-02-08 | Exercise or conversion : show line 8 in the form 10b5-1 Stock Option (right to buy) | −14,148 | 0 | D |
| 2024-02-08 | Exercise or conversion : show line 9 in the form 10b5-1 Stock Option (right to buy) | −34,931 | 0 | D |
| 2024-02-08 | Exercise or conversion : show line 10 in the form 10b5-1 Stock Option (right to buy) | −140,000 | 0 | D |
Loading xslF345X05/doc4.xml…